Barclays analyst Marc Solecitto maintains Aris Water Solutions (NYSE:ARIS) with a Equal-Weight and lowers the price target from $18 to $15.
BrainStorm Cell Therapeutics Presents NurOwn Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress
BrainStorm Cell Therapeutics Inc.